2 completed, 1 terminated. 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Terminated 1 |
Follow CPI-006: new trials by email Literature Review of CPI-006 trials Research Report on CPI-006
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC - Covid-19 | Phase 3 | Terminated | Corvus Pharmaceuticals, Inc. | 46 | 2021-02-25 | 2022-09-21 |
| Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients CPI-006, Standard of Care - COVID-19 | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 30 | 2020-07-01 | 2021-07-21 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab - Non-Small Cell Lung Cancer, Renal Cell Cancer | Phase 1 | Completed | Corvus Pharmaceuticals, Inc. | 117 | 2018-04-25 | 2023-12-21 |
COVID-19 (2) · Coronavirus Infections (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1) · Sarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Corvus Pharmaceuticals, Inc. (3)
United States (3) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Germany (1) · Italy (1) · Mexico (1) · Peru (1) · Spain (1) · Ukraine (1)
S Mahabhashyam, MD (1) · S. Mahabhashyam, MD, MPH (1) · S. Mahabhashyam, MD. MPH (1)